… (b) is recreated based on a figure by Wikimedia user ‘Dcirovic.’ Licensed under CC0 via …
called a pharmacophore model (see Figure 5(b)), containing the chemical features deemed to …

… The main reason for this change is probably an article by Readhead et al. describing the …
Ben Readhead. I suspect that the interest has been present in ‘latent’ form for some time …

… (b) Quantification of head size phenotype in each treatment condition as compared to
control embryos for furin MO (N control = 76, N furin MO = 66, P = 5.32 × 10 −20 ), TSNARE1 (N …

… , doxorubicin, vincristine and prednisone) for the treatment of diffuse large B-cell lymphoma
… on off-targeting of the molecule agains EGF receptor and cytosolic protein kinase B [129] …

… –E) Regulatory networks built across EC and HIP samples showed differences in gene
drivers for preclinical AD versus control networks (B) including many AD associated genes (C), …

… (b,c) Quantitative analyses of the blots revealed elevated levels of RIPK1 (t(21) = 3.444, P =
0.002 for RIPA; t(21) = 2.205, P = 0.038 for urea) and MLKL (t(21) = 2.443, P = 0.023 for RIPA…

… (a, b) Histograms of the significance scores for the 8,301 signatures from the LJP5 and
LJP6 batches. (c) Correlation between the strength metrics for signatures computed by the two …

… (B) Representative colony-formation assays and quantifications … (B). (D) Flow cytometry
detection of Annexin V and PI in the same cells and following the same treatments described in (B…

… þ , Figures 2A and 2C) or remained level (REMC brain-specific, Figure 2B). Though there …
(B) Same hypothetical GWAS and eQTL signatures after the all-but-one conditional eQTL …

Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all patients
and efficacy is limited by common, often severe, side-effects. Genetic studies of disease …